Literature DB >> 10952619

Successful trovafloxacin prophylaxis against experimental streptococcal aortic valve endocarditis.

I Katsarolis1, A Pefanis, D Iliopoulos, P Siaperas, P Karayiannakos, H Giamarellou.   

Abstract

Single-dose trovafloxacin (15 mg/kg given intravenously [i.v.]) and ampicillin (40 mg/kg given i.v.) protected 38 and 33% of animals challenged with an ampicillin-tolerant strain of Streptococcus oralis, respectively. As a double-dose regimen, trovafloxacin afforded total protection (100%; P < 0.001 versus controls). Trovafloxacin is the first fluoroquinolone effective in preventing experimental streptococcal endocarditis.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10952619      PMCID： PMC90109          DOI： 10.1128/AAC.44.9.2564-2566.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

1.  Pharmacokinetics of 18F-labeled trovafloxacin in normal and Escherichia coli-infected rats and rabbits studied with positron emission tomography.

Authors:  Alan J. Fischman; John W. Babich; Nathaniel M. Alpert; John Vincent; Robert A. Wilkinson; Ronald J. Callahan; John A. Correia; Robert H. Rubin
Journal:  Clin Microbiol Infect       Date:  1997-02       Impact factor: 8.067

2.  Efficacy of trovafloxacin in treatment of experimental staphylococcal or streptococcal endocarditis.

Authors:  J M Entenza; J Vouillamoz; M P Glauser; P Moreillon
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

3.  Successful single-dose teicoplanin prophylaxis against experimental streptococcal, enterococcal, and staphylococcal aortic valve endocarditis.

Authors:  G S Perdikaris; A Pefanis; H Giamarellou; A Nikolopoulos; E P Margaris; I Donta; A Tsitsika; P Karayiannakos
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

4.  Chemoprophylactic efficacy against experimental endocarditis caused by beta-lactamase-producing, aminoglycoside-resistant enterococci is associated with prolonged serum inhibitory activity.

Authors:  A S Bayer; J Tu
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

5.  In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria.

Authors:  G M Eliopoulos; K Klimm; C T Eliopoulos; M J Ferraro; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

6.  Efficacy of ciprofloxacin in treatment and prophylaxis of experimental Staphylococcus aureus endocarditis caused by a cloxacillin-tolerant strain and its non-tolerant variant.

Authors:  G P Voorn; J Thompson; W H Goessens; W C Schmal-Bauer; P H Broeders; M F Michel
Journal:  J Antimicrob Chemother       Date:  1994-04       Impact factor: 5.790

7.  Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers.

Authors:  R Teng; S C Harris; D E Nix; J J Schentag; G Foulds; T E Liston
Journal:  J Antimicrob Chemother       Date:  1995-08       Impact factor: 5.790

8.  Mechanisms of successful amoxicillin prophylaxis of experimental endocarditis due to Streptococcus intermedius.

Authors:  P Moreillon; P Francioli; D Overholser; P Meylan; M P Glauser
Journal:  J Infect Dis       Date:  1986-11       Impact factor: 5.226

9.  Successful single-dose amoxicillin prophylaxis against experimental streptococcal endocarditis: evidence for two mechanisms of protection.

Authors:  M P Glauser; J P Bernard; P Moreillon; P Francioli
Journal:  J Infect Dis       Date:  1983-03       Impact factor: 5.226

10.  Experimental endocarditis. II. Staphylococcal infection of the aortic valve following placement of a polyethylene catheter in the left side of the heart.

Authors:  B B Perlman; L R Freedman
Journal:  Yale J Biol Med       Date:  1971-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.